Mechanisms of antiarrhythmic drug action on termination of atrial flutter

PACE - Pacing and Clinical Electrophysiology

Volumn 24, Issue 5, 2001, Pages 824-834

  Tai, Ching Tai ^a   Chen, Shih Ann ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Antiarrhythmic drugs; Atrial flutter

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMIODARONE; ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; IBUTILIDE; LIDOCAINE; MEXILETINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL;

ARTICLE; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; HEART ATRIUM FLUTTER; HEART CONDUCTION; HEART CYCLE; HEART PROARRHYTHMIA; HUMAN; OSCILLATION; REENTRY ARRHYTHMIA;

EID: 0035003792     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2001.00824.x     Document Type: Article

References (93)

1. 1. Frame LH. Lessons from animal models of atrial arrhythmias. Cardiol Clin 1996; 14:471-481.
2. 2. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins, N Engl J Med 1998; 339:659-666.
3. 3. Chen SA, Hsieh MH,Tai CT, etal. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: Electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100:1879-1886.
4. 4. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for acute termination of atrial fibrillation and atrial flutter: A dose response study. J Am Coll Cardiol 1996; 28:130-136.
5. 5. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94:1613-1621
6. 6. Falk RH, Pollak A, Singh SN, et al. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter, J Am Coll Cardiol 1997; 29:385-390.
7. 7. Campbell RWF. Pharmacologic therapy of atrial flutter, J Cardiovasc Electrophysiol 1996; 7:1008-1012.
8. 8. Rosenbleuth A, Garcia Ramos J. Studies on flutter and fibrillation: II. The influence of artificial obstacles on experimental auricular flutter. Am Heart J 1947; 33:677-684.
9. 9. Frame LH, Page RL, Hoffman BF. Atrial reentry around an anatomic barrier with a partially refractory excitable gap: A canine model of atrial flutter. Circ Res 1986; 58:495-511.
10. 10. Feld GK, Shahandeh-Rad F. Activation patterns in experimental canine atrial flutter produced by right atrial crush injury, J Am Coll Cardiol 1992; 20:441-451.
11. 11. Allessie MA, Lammers WJ, Bonke IM, et al. Intraatrial reentry as a mechanism for atrial flutter induced by acetylcholine and rapid pacing in the dog. Circulation 1984; 70:123-135.
12. 12. Page PL, Plumb VJ, Okumura K, et al. A new model of atrial flutter. J Am Coll Cardiol 1986; 8:872-879.
13. 13. Boyden PA. Activation sequence during atrial flutter in dogs with surgically induced right atrial enlargement: I. Observations during sustained rhythms. Circ Res 1988; 62:596-608.
14. 14. Puech P, Latour H, Grolleau R. Le flutter et ses limites. Arch Mal Coeur 1970; 63:116-144.
15. 15. Klein GJ, Guiraudon GM, Sharma AD, et al. Demonstration of macroreentry and feasibility of operative therapy in the common type of atrial flutter. Am J Cardiol 1986; 57:587-591.
16. 16. Olshansky B, Okumura K, Hess PG, etal. Demonstration of an area of slow conduction in human atrial flutter. J Am Coll Cardiol 1990; 16:1639-1648.
17. 17. Cosio FG, Lopez-Gil M, Goicolea A, et al. Electrophyslologic studies in atrial flutter. Clin Cardiol 1992; 15:667-673.
18. 18. Tai CT, Chen SA, Chiang CE, et al. Electrophysiologic characteristics and radiofrequency catheter ablation in patients with clockwise atrial flutter. J Cardiovasc Electrophysiol 1997; 8:24-34.
19. 19. Saoudi N, Nair M, Abdelaziz A, et al. Electrocardiographic patterns and results of radiofrequency catheter ablation of clockwise type I atrial flutter. J Cardiovasc Electrophysiol 1996; 7:931-942.
20. 20. Olgin JE, Kalman JM, Fitzpatrick AP, et al. Role of right atrial endocardial structures as barriers to conduction during human type I atrial flutter: Activation and entrainment mapping guided by intracardiac echocardiography. Circulation 1995; 92:1839-1848.
21. 21. Kalman JM, Olgin JE, Saxon LA, et al. Activation and entrainment mapping defines the tricuspid annulus as the anterior barrier in typical atrial flutter. Circulation 1996; 94:398-406.
22. 22. Shah DC, Jais PJ, Halssaguerre M. et al. Three-dimensional mapping of the common atrial flutter circuit in the right atrium. Circulation 1997; 96:3904-3912.
23. 23. Kall JG, Rubenstein DS, Kopp DE, et al. Atypical atrial flutter originating in the right atrial free wall. Circulation 2000; 101:270-279.
24. 24. Jais P, Shah DC, Haissaguerre M, et al. Mapping and ablation of left atrial flutter. Circulation 2000; 101:2928-2934.
25. 25. Tai CT, Chen SA, Chiang CE, et al. Characterization of low right atrial isthmus as the slow conduction zone and pharmacological target in typical atrial flutter. Circulation 1997; 96:2601-2611.
26. 26. Feld GK, Mollerus M, Birgersdotter-Green U, et al. Conduction velocity in the tricuspid valve-inferior vena cava isthmus is slower in patients with type I atrial flutter compared to those without a history of atrial flutter. J Cardiovasc Electrophysiol 1997; 8:1338-1348.
27. 27. Spach MS, Dolber PC, Heidlage JF. Influence of the passive anisotropic properties on directional differences in propagation following modification of the sodium conductance in human atrial muscle: A model of reentry based on anisotropic discontinuous propagation. Circ Res 1988; 62:811-832.
28. 28. Spach MS, Dolber PC. Relating extracellular potentials and their derivatives to anisotropic propagation at a microscopic level in human cardiac muscle: Evidence for electrical uncoupling of side-to-side fiber connections with increasing age. Circ Res 1986; 58:356-371.
29. 29. Cabrera JA, Sanchez-Quintana S, Ho SY, et al. The architecture of the atrial musculature between the orifice of the inferior cava vein and the tricuspid valve: The anatomy of the isthmus. J Cardiovasc Electrophysiol 1998; 9:1186-1195.
30. 30. Boineau JP, Schuessller RB, Mooney CR, et al. Natural and evoked atrial flutter due to circus movement in dogs. Am J Cardiol 1980; 45:1167-1181.
31. 31. Tai CT, Chen SA, Chen YJ, et al. Conduction properties of the crista terminalis in patients with typical atrial flutter: Basis for a line of block in the reentrant circuit. J Cardiovasc Electrophysiol 1998; 9:811-819.
32. 32. Arenal A, Almendral J, Alday J, et al. Rate dependent conduction block of the crista terminalis in patients with typical atrial flutter: Influence on evaluation of cavotricuspid isthmus conduction block. Circulation 1999; 99:2771-2778.
33. 33. Friedman PA, Luria D, Fenton AM, et al. Global right atrial mapping of human atrial flutter: The presence of posteromedial (sinus venosa region) functional block and double potentials. A study in biplane fluoroscopy and intracardiac echocardiography. Circulation 2000; 101:1568-1577.
34. 34. Bella PD, Marenzi G, Tondo C, et al. Usefulness of excitable gap and pattern of resetting in atrial flutter for determining reentry circuit location. Am J Cardiol 1991; 68:492-497.
35. 35. Callans DJ, Schwartzman D, Gottlieb CD, et al. Characterization of the excitable gap in human type I atrial flutter. J Am Coll Cardiol 1997; 30:1793-1801.
36. 36. Harrison DC. Antiarrhythmic drug classification: New science and practical application. Am J Cardiol 1985; 56:185-190.
37. 37. Nattel S, Relationship between use dependent effect of antiarrhythmic drugs on conduction and Vmax in canine cardiac Purkinje fibers. J Pharmacol Exp Ther 1987; 241:282-288.
38. 38. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms, Circulation 1991; 84:1831-1851.
39. 39. Wu KM, Hoffman BF. Effect of procainamide and N-acetylprocainamide on atrial flutter: Studies in vivo and in vitro. Circulation 1987:6:1397-1408.
40. 40. Schoels W, Gough WB, Restivo M, et al. Circus movement atrial flutter in the canine sterile pericarditis model: Activation patterns during initiation, termination, and sustained reentry in vivo. Circulation 1990; 67:35-50.
41. 41. Stambler BS, Wood MA, Ellenbogen KA. Pharmacologic alterations in human type I atrial flutter cycle length and monophasic action potential duration. J Am Coll Cardiol 1996; 27:453-461.
42. 42. Spinelli W, Hoffman BF. Mechanisms of termination of reentrant atrial arrhythmias by class I and class III antiarrhythmic agents. Circ Res 1989; 65:1565-1579.
43. 43. Derakhchan K, Page P, Lambert C, et al. Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia. J Pharmacol Exp Ther 1994; 270:47-54.
44. 44. Inoue H, Yamashita T, Nozaki A, et al. Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: Role of prolongation of refractory period and depression of conduction to excitable gap. J Am Coll Cardiol 1991; 18:1098-1104.
45. 45. Tai CT, Chen SA, Feng AN, et al. Electropharmacologic effects of class I and class III antiarrhythmic drugs on typical atrial flutter: Insights into the mechanism of termination, Circulation 1998; 97:1935-1945.
46. + current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992; 262:99-108.
47. 47. Hondeghen LM, Snyders DT. Class III antiarrhythmic agents have a lot of potential, but a long way to go: Reduced effectiveness and dangers of reverse use dependence. Circulation 1990; 81:686-690.
48. 48. Boyden PA, Graziano JN, Activation mapping of reentry around an anatomical barrier in the canine atrium: Observations during the action of the class III agent, d-sotalol. J Cardiovasc Electrophysiol 1993; 4:266-279.
49. 49. Feld GK, Venkatesh N, Singh BN. Pharmacologic conversion and suppression of experimental canine atrial flutter: Differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction. Circulation 1986; 74:197-204.
50. 50. Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double blinded, placebo-controlled study. Am Heart J 1995; 129:739-748.
51. 51. Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over dl-sotalol in converting atrial flutter and fibrillation. Heart 1998; 79:568-575.
52. 52. Platou ES, Refsum H, Class III antiarrhythmic action in experimental atrial fibrillation and flutter in dogs. J Cardiovasc Pharmacol 1982; 4:839-846.
53. 53. Vietti-Ramus G, Veglio F, Marchisio U, et al. Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmia. Int J Cardiol 1992; 35:77-85.
54. 54. Buchanan LV, Turcotte VM, Kabell G, et al. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol 1993; 33:10-14.
55. 55. Buchanan LV, Kabell G, Gibson JK. Acute intravenous conversion of canine atrial flutter: Comparison of antiarrhythmic agents. J Cardiovasc Phamacol 1995; 25:539-544.
56. 56. Buchanan LV, LeMay RJ, Walters RR, et al. Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model. J Cardiovasc Electrophysiol 1996; 7:113-119.
57. 57. Cha Y, Wales A, Wolf P, et al. Electrophysiologic effects of the new class III antiarrhythmic drug dofetllide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter; Role of dispersion of refractoriness in antiarrhythmic efficacy. J Cardiovasc Electrophysiol 1996; 7:809-827.
58. 58. Norgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and atrial flutter: A multicenter, randomized, double-blinded, placebo-controlled trial. Am Heart J 1999; 137:1062-1069.
59. 59. Cheng J, Cabeen WR Jr, Scheinman MM. Right atrial flutter due to lower loop reentry: Mechanisms and anatomic substrates. Circulation 1999; 99:1700-1705.
60. 60. Guo GBF, Ellenbogen KA, Wood MA, et al. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol 1996; 27:1083-1089.
61. 61. Frame LH, Simson MB. Oscillations of conduction, action potential duration, and refractoriness, A mechanism for spontaneous termination of reentrant tachycardias. Circulation 1988; 78:1277-1287.
62. 62. Frame KH, Rhee EK. Spontaneous termination of reentry after one cycle or short nonsustained runs. Role of oscillations and excess dispersion of refractoriness. Circ Res 1991; 68:493-502.
63. 63. Restivo M, Hegazy M, Caref EB, et al. Effects of azimilide dihydrochloride on circus movement atrial flutter in the canine sterile pericarditis model. J Cardiovasc Electrophysiol 1996; 7:612-624.
64. 64. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation. Circulation 1997; 96:4298-4306.
65. 65. Volgman AS, Carberry PA, Stambler BS, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998; 31:1414-1419.
66. 66. Crijns HJGM, Van Gelder IC, Kingma JH. et al. Atrial flutter can be terminated by a class III antiarrhythmic drugs but not by a class IC drug. Eur Heart J 1994; 15:1403-1408.
67. 67. Olshansky B, Okumura K, Hess PG, et al. Use of procainamide with rapid atrial pacing for successful conversion of atrial flutter to sinus rhythm. J Am Coll Cardiol 1988; 11:359-364.
68. 68. Della Bella P, Tondo C, Marenzi G, et al. Facilitating influence of disopyramide on atrial flutter termination by overdrive pacing. Am J Cardiol 1988; 61:1046-1049.
69. 69. Heldal M, Orning OM. Effects of flecainide on termination of atrial flutter by rapid atrial pacing. Eur Heart J 1993; 14:421-424.
70. 70. Doni F, Della Bella P, Kheir A, et al. Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. Am J Cardiol 1995; 76:1243-1246.
71. 71. Stambler BS, Wood MA, Ellenbogen KA. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 1996; 77:960-966.
72. 72. Matiouchine GV, Shulman VA, Balog AI, et al. Combined transesophageal left atrial pacing and antiarrhythmic therapy in the treatment of atrial flutter. PACE 1996; 19:1947-1950.
73. 73. D'Este D, Bertaglia E, Mantovan R, et al. Efficacy of intravenous propafenone in termination of atrial flutter by overdrive transesophageal pacing previously ineffective. Am J Cardiol 1997; 79:500-502.
74. 74. Heisel A, Jung J, Stopp M, et al. Facilitating influence of procainamide on conversion of atrial flutter by rapid atrial pacing. Eur Heart J 1997; 18:866-869.
75. 75. Murdock CJ, Kyles AE, Yeung-Lai-Wah JA, et al. Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990; 66:755-757.
76. 76. Feld GK, Chen PS, Nicod P, et al. Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs. Am J Cardiol 1990; 66:378-383.
77. 77. Huang DT, Monohan KM, Zimetbaum P, et al. Hybrid pharmacologic and ablative therapy: A novel and effective approach for the management of atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9:462-469.
78. 78. Tai CT, Chiang CE, Lee SH, et al. Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: Electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. J Cardiovasc Electrophysiol 1999; 10:1180-1187.
79. 79. Schumacher B, Jung W, Lewalter T, et al. Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. Am J Cardiol 1999; 83:710-713.
80. 80. Nabar A, Rodriguez LM, Timmermans C, et al. Radiofrequency ablation of class IC atrial flutter in patients with resistant atrial fibrillation, Am J Cardiol 1999; 83:785-787.
81. 81. Page PL, Hassanalizadeh H, Cardinal R. Transition among atrial fibrillation, atrial flutter, and sinus rhythm during procainamide infusion and vagal stimulation in dogs with sterile pericarditis. Can J Physiol Pharmacol 1991; 69:15-24.
82. 82. Roithinger FX, Karch MR, Stener PR, et al. Relationship between atrial fibrillation and typical atrial flutter in humans: Activation sequence changes during spontaneous conversion, Circulation 1997; 96:3484-3491.
83. 83. Kowey PR, VanderLugt JT, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation /flutter. Am J Cardiol 1996; 78:46-52.
84. 84. Wang Q, Chen Q, Li H, et al. Molecular genetics of long QT syndrome from genes to patients, Curr Opin Cardiol 1997; 12:310-320.
85. 85. Roden DM, Spooner PM, Inherited long QT syndromes: A paradigm for understanding arrhythmogenesis, J Cardiovasc Electrophysiol 1999; 10:1664-1683.
86. 86. Fermini B, Jurkiewicz NK, Jow B, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: Block of delayed rectifier and L-type calcium currents. J Cardiovasc Pharmacol 1995; 26:259-271.
87. 87. Karam R, Marcello S, Brooks RR. et al. Azimilide dihydrocholoride, a novel antiarrhythmic agent. Am J Cardiol 1998; 81:40-46.
88. 88. Page RL, Conolly SJ, Marcello SR, et al. Dose response for azimilide treatment of paroxysmal supraventricular tachycardias. (abstract) Can J Cardiol 1999; 15(Suppl. D):144D.
89. 89. Conolly SJ, Pritchett ELC, Page RL, et al. Survival in patients treated with azimilide for atrial fibrillation and other supraventricular arrhythmias. (abstract) Can J Cardiol 1999; 15(Suppl. D):136D.
90. 90. Bargheer K, Bode F, Klein HU, et al. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur Heart J 1994; 15:1409-1414.
91. 91. Wallace AA, Stupienski RF, Baskin EP, et al. Cardiac electrophysiologic antiarrhythmic actions of tedisamil. J Pharmacol Exp Ther 1995; 273:168-175.
92. 92. Fischbach PS, Johnston PV, Friedrichs GS, et al. Tedisamil in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol 1999; 34:212-218.
93. 93. Rahme MM, Cotter B, Leistad E, et al. Electrophysiological and antiarrhymic effects of the atrial selective 5-HT4 receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation 2000; 100:2010-2017.